Oruka Therapeutics, Inc.
General ticker "ORKA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Oruka Therapeutics, Inc. follows the US Stock Market performance with the rate: 54.8%.
Estimated limits based on current volatility of 4.1%: low 88.90$, high 96.51$
Factors to consider:
- Earnings expected soon, date: 2026-08-10 bmo
- Total employees count: 68 (+142.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: No approved products, Clinical trial failure, Inability to raise capital, Regulatory and compliance, Labor/talent shortage/retention
- Current price 109.6% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.67$, 46.03$]
- 2026-12-31 to 2027-12-31 estimated range: [10.08$, 29.83$]
Financial Metrics affecting the ORKA estimates:
- Negative: with PPE of -16.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.21 <= 0.30
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 96.58 > 63.79
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Industry earnings per price (median), % of -12.84 <= 0
Short-term ORKA quotes
Long-term ORKA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $7.30MM | $88.12MM | $122.05MM |
| Operating Income | $-7.30MM | $-88.12MM | $-122.05MM |
| Non-Operating Income | $1.96MM | $4.40MM | $16.62MM |
| Interest Expense | $0.00MM | $1.47MM | $0.00MM |
| R&D Expense | $1.01MM | $75.06MM | $100.64MM |
| Income(Loss) | $-5.34MM | $-83.72MM | $-105.43MM |
| Net Income(Loss)* | $-5.34MM | $-83.72MM | $-105.43MM |
| Stockholders Equity | $37.02MM | $382.22MM | $471.93MM |
| Assets | $37.86MM | $396.02MM | $488.62MM |
| Operating Cash Flow | $-5.01MM | $-57.84MM | $-88.21MM |
| Capital expenditure | $0.00MM | $0.19MM | $0.21MM |
| Investing Cash Flow | $0.00MM | $-330.13MM | $-96.75MM |
| Financing Cash Flow | $0.00MM | $449.54MM | $170.31MM |
| Earnings Per Share** | $-0.37 | $-4.99 | $-2.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.